Loading patent…
AssigneeCrystal Pharmatech Co., Ltd.
InventorsMinhua CHEN, Yanfeng ZHANG, Kai LIU, Xiaoyu ZHANG
Estimating the term…
The present disclosure disclosed crystalline forms of Filgotinib hydrochloride for treating or preventing JAK-associated diseases, and preparation methods, pharmaceutical compositions, and formulations thereof. The present disclosure also disclosed the use of crystalline forms of Filgotinib hydrochloride in the prevention and/or treatment of diseases associated with JAK family. In comparison to the known crystalline forms, the crystalline forms of the present disclosure show more favorable properties in terms of formulation engineering, such as higher stability under low water activity conditions, simplicity in the preparation process and/or higher solubility.
A crystalline Form B of Filgotinib hydrochloride with the following chemical structure, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 7.1°±0.2°, 13.2°±0.2° and 14.2°±0.2° using Cu-Kα radiation.
A crystalline Form A of Filgotinib hydrochloride with the following chemical structure, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 7.3°±0.2°, 14.7°±0.2° and 29.6°±0.2° using Cu-Kα radiation.
A crystalline Form C of Filgotinib hydrochloride with the following chemical structure, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 7.0°±0.2°, 14.0°±0.2° and 20.5°±0.2° using Cu-Kα radiation.
A crystalline Form D of Filgotinib hydrochloride with the following chemical structure, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 7.0°±0.2°, 10.7°±0.2° and 17.1°±0.2° using Cu-Kα radiation.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.